1. Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae, and porcine circovirus type 2 on a 3 pathogen challenge model.
- Author
-
Jeong J, Kang I, Kim S, Park KH, Park C, and Chae C
- Subjects
- Animals, Bacterial Vaccines administration & dosage, Bacterial Vaccines immunology, Circoviridae Infections immunology, Circoviridae Infections prevention & control, DNA, Viral blood, Mycoplasma hyopneumoniae immunology, Pneumonia of Swine, Mycoplasmal microbiology, Porcine Reproductive and Respiratory Syndrome virology, Porcine respiratory and reproductive syndrome virus immunology, RNA, Viral blood, Swine, Swine Diseases microbiology, Swine Diseases prevention & control, Swine Diseases virology, Time Factors, Viral Vaccines administration & dosage, Viral Vaccines immunology, Viremia veterinary, Circoviridae Infections veterinary, Circovirus classification, Circovirus immunology, Pneumonia of Swine, Mycoplasmal prevention & control, Porcine Reproductive and Respiratory Syndrome prevention & control, Vaccination veterinary
- Abstract
The objective of this study was to compare clinical, microbiologic, immunologic, and pathologic parameters in pigs each concurrently administered porcine reproductive and respiratory syndrome virus (PRRSV), Mycoplasma hyopneumoniae, and porcine circovirus type 2 (PCV2) vaccine from 1 of 2 commercial sources at 21 days of age and challenged with field strains of each of the 3 pathogens. Pigs were challenged with PRRSV and M. hyopneumoniae at 42 days of age (-14 days post-challenge, dpc) followed by a challenge with PCV2 at 56 days of age (0 dpc). Significant differences were observed between vaccinated challenged and unvaccinated challenged groups in clinical (average daily gain and clinical signs), microbiologic (viremia and nasal shedding), immunologic (antibodies and interferon-γ secreting cells), and pathologic (lesions) outcomes. Significant differences were observed among the 3 vaccinated challenged groups in microbiologic (nasal shedding of M. hyopneumoniae and viremia of PCV2) and immunologic ( M. hyopneumoniae - and PCV2-specific interferon-γ secreting cells) outcomes. The vaccination regimen for PRRSV vaccine, M. hyopneumoniae vaccine, and PCV2 vaccine is efficacious for controlling triple challenge with PRRSV, M. hyopneumoniae, and PCV2 from weaning to finishing period.
- Published
- 2018